The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...

The ongoing Daro-PET study set out to evaluate the ability of the oral androgen receptor inhibitor darolutamide (Nubeqa) to ...

An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO ...

lab assistant_TS_506712196 PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens. Prostate-specific membrane ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Renu Eapen discussing the optimal management of de-novo ...

Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic ...

The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer. Key areas include expansion in radioligand therapy and ...